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A b s t r a c t  
The objective of the present study is the preparation and characterization of Amphotericin B-loaded 
poly(DL-lactide-co-caprolactone) microspheres. The microspheres were prepared based on o/w 
emulsion solvent evaporation technique by varying the quantity of drug introduced. Characterization 
experiments included drug encapsulation efficiency, drug loading, particle size, morphology, FT-IR, 
stability, and drug release study. The drug encapsulation and drug loading increased with increasing 
drug mass. The microspheres exhibited homogeneous particle sizes with a spherical shape and 
porous surface. FT-IR spectrum of drug-loaded microspheres confirmed the absence of polymer-
drug interaction. The stability study showed no major difference in the degradation of microspheres 
after 3 months of storage. Finally, the in vitro drug release behavior of the prepared formulations 
revealed a sustained release profile, with a burst effect for the formulations with the highest drug 
loadings.  
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Introduction 
Targeted drug delivery has gained a great importance in medical 
and pharmaceutical research. All Drug Delivery Systems (DDS) 
should include continuous regulation of drug levels with the 
therapeutic range, effective targeted delivery, reduction in the 
amount of drug needed, and, as consequence, a decrease in 
toxicity and side effects [1-6]. 
Microspheres and microcapsules based on biodegradable 
polyesters have received much attention in recent years as DDS. 
They are suitable for the controlled and sustained release of many 
pharmaceutical agents. Polymeric microspheres can be produced 
using several techniques such as solvent evaporation, spray 
drying, coacervation, etc. The most common technique for the 
formulation of microspheres is the emulsion solvent evaporation 
technique. It is widely used because it is a relatively simple and 
inexpensive method which enables the encapsulation of a broad 
variety of drugs [7, 8].  
Many polymeric particulate carriers have been used for protecting 
the active molecules and for controlling their release in body fluids. 
Poly(lactic acid) (PLA) and its copolymers are well known 
biodegradable carriers in drug delivery, for bonding fractures, and 
as resorbable sutures [9-14]. Poly(ē-caprolactone) (PCL) is also an 
aliphatic polyester which is very suitable for controlled drug 
delivery, due to its high permeability to many drugs and non-
toxicity, and very slow degradation rate [15]. Poly(DL-lactide-co-
caprolactone) (PLC) is obtained by varying the composition of PLA 
and PCL copolymers, thus modifying the degradation profile of the 
co-polymer [16, 17, 21]. 
Many pharmaceutical agents have been microencapsulated within 
PLC showing promising interest for this polymer as a DDS. These 
include đ-lipoic acid for the prevention of neointimal formation in 
vivo [17], the anti-inflammatory agent Colchicine for the treatment 
of restenosis [18], the anti-cancer drug Cisplatin [19], and the non-
steroidal drug Ibuprofen [20]. PLC has been also used to produce a 
substitute for various tissue repair applications [21].  
The antifungal drug Amphotericin B (AmB) has showed a major 
importance in DDS through formulation of microspheres in order to 
decrease its side effects while providing a controlled release of it 
[3, 4]. These side effects have resulted from its insolubility and 
instability in water, as well as its great acute toxicity which could 
prohibit its direct therapeutic uses [22, 23]. In this context, the main 
objective of the present study is to investigate the possibility of 
formulating a new DDS based on AmB-loaded PLC microspheres. 
Characterization of the prepared model system then has been 
carried out. 
Materials and Methods 
Materials 
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Amphotericin B, Poly(DL-lactide-co-caprolactone) (86 mol% DL-
lactide), the surfactant tween 80, and phosphate buffered saline 
(PBS) (0.2 M, pH 7.4) are purchased from Sigma-Aldrich, Chemie 
Germany. The solvents dichloromethane and methanol are of 
analytical grade. 
 
Microspheres preparation 
O/W emulsion solvent evaporation technique was used for the 
preparation of microspheres. Different formulations were prepared 
and referenced F1 to F5 by fixing the quantity of polymer and the 
surfactant, and changing the quantity of drug introduced.  
Each synthesis consisted of dissolving 500 mg of the polymer PLC 
and a different mass of the drug in 20 ml 
dichloromethane/methanol at a ratio 14:6, forming the organic 
phase. This mixture was added into an aqueous solution containing 
250 ml water and 45 g Tween 80 used as surfactant. The o/w 
emulsion was continually stirred for 6 hours at room temperature, 
and at 1400 rpm over a mechanical stirrer (MSP-1 Digital 
Overhead Stirrer, Jeiotech, Korea). The formed microspheres were 
filtered and washed with distilled water and 10 ml methanol. They 
were then dried at 40ĈC for 48 hours.  
 
Microspheres characterization 
Drug Encapsulation (%EE) and Drug Loading (%DL) : 
%EE and %DL were evaluated using UV/vis spectrophotometry 
(Nicolet Evolution 300, Thermo-Scientific, UK). For this, 7 mg of 
each microsphere formulation were dissolved in 7:3 ml 
dichloromethane/methanol. They were then assessed for their 
AmB content at 409 nm. %EE and %DL were calculated according 
to the following equations: 
%EE = 
mass drug Introduced
mass drug edEncapsulat
*100 
 
%DL = 
mass esMicrospher
mass drug edEncapsulat
*100 
Particle size measurement: 
A laser diffraction granulometer (LA-950A2 instrument, Horiba Ltd., 
France) was used to measure the particle size of microspheres. 
For this purpose, a small quantity of microspheres was suspended 
in water, with few drops of Tween 80, used as dispersing agent. 
The average particle size obtained was expressed in micrometers. 
 
Morphology study 
The morphological characteristics of the prepared microspheres 
were examined using Scanning Electron Microscopy (SEM) 
(LYRA3 XMU, TESCAN, Czech Republic). Microspheres were 
mounted on metal stubs with conductive silver paint, and then 
sputtered with a thin gold layer. 
 
Fourier Transform-Infrared (FT-IR) study 
Spectra for AmB, PLC, and AmB-loaded microspheres were 
recorded on a FT-IR spectrometer (Nicolet IS10, Thermo-Scientific, 
UK) using the Attenuated Total Reflectance Technique (ATR). In 
this method, the sample is held in contact with an optically dense 
crystal with a high refractive index for testing. 
 
Stability study 
The stability study was carried over a period of 3 months to follow 
the changes in the morphological state of the polymer inside the 
matrix material at different environmental conditions (4ĈC, 25ĈC, 
and 37ĈC). Every month, a certain quantity of the stored 
microspheres was examined by Optical Microscopy (LEICA DM 
LS2, Vashaw Scientific Inc., USA) 
 
In Vitro drug release study 
The drug release experiments were conducted in PBS. 25 mg 
microspheres were suspended in 25 ml PBS into a vial rotated at 
150 rpm and maintained at 37ĈC. At pre-determined time intervals, 
5 ml of the release medium was withdrawn and replaced by fresh 
solution. The drug content of this release medium was determined 
at 409 nm.  
Results and Discussion 
In this study, o/w emulsion solvent evaporation technique known 
for its simplicity, reproducibility and good results was chosen as the 
method for the formulation of AmB-loaded PLC microspheres.  
Results concerning the %EE, %DL, and particle size are 
summarized in Table 1.  
The %EE increased with increasing quantity of drug introduced, 
from 51% to 81%. %EE then decreased due to a saturated 
capacity of the polymeric matrix system. As for the % DL, the 
results revealed an increasing trend from 0.05% to 0.16% (Table 
1). The high %EE could be explained by the hydrophobic nature of 
the drug and its great affinity to the amphiphilic copolymer used, 
that was able of solubilizing the drug inside the microspheres [3, 4]. 
Since AmB is insoluble in the aqueous phase, it has a higher 
tendency towards the organic phase during the microencapsulation 
process. As the quantity of drug introduced increased, more of the 
drug was able to be incorporated into the matrix system, which 
yielded high %EE and %DL values. In comparison with the other 
antifungal agent Nystatin, which was also encapsulated within PLC 
microspheres, the maximum %EE was found 20% [1, 2]. This 
relatively low encapsulation obtained with Nystatin could be 
attributed to the difference in solubility between the two antifungal 
drugs in the water-miscible co-solvent methanol.  
Concerning the particle size of microspheres, it was homogeneous 
and had an average of 85 øm for all the formulations (Table 1). 
This result showed the suitability of AmB microspheres for oral 
administration. 
SEM microphotographs of drug-loaded PLC microspheres revealed 
a spherical profile, with a rough and porous surface (Figure 1). 
The physicochemical stability and compatibility studies were 
performed through FT-IR spectroscopy. FT-IR spectra were 
recorded for AmB, PLC and AmB-loaded microspheres. 
Comparison of the characteristic bands among the three spectra 
didnÊt reveal any large shift or deviation in the spectrum of the drug 
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when formulated into microspheres (Figures 2, 3, and 4). This 
result confirmed the absence of any drug-polymer interaction. 
 
 
Table 1.Drug encapsulation, drug loading and average particle size of AmB-loaded PLC microspheres 
Formulation 
Code Quantity of AmB (mg) 
Encapsulation Efficiency 
(%) 
Drug Loading 
(%) Average Particle 
Size (øm) 
F1 35 51 0.05 86 
F2 50 67 0.093 84 
F3 60 74 0.14 80 
F4 70 81 0.16 87 
F5 75 57 0.12 84 
 
 
Figure 1. (a) SEM 3D stereoscopic image of AmB-loaded PLC microspheres, (b) SEM photograph of a porous microsphere (10,000x 
magnifications) 
 
Figure 2.FT-IR spectrum for AmB 
(a (b)
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Figure 3.FT-IR spectrum for PLC 
 
 
 
 
Figure 4.FT-IR Spectrum for AmB-loaded PLC microspheres 
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Figure 5.Microphotographs of microspheres after 3 months of storage 
 
 
Figure 6.In vitro drug release profiles for AmB-loaded PLC microspheres formulations. 
 
 
 
Several bands in the spectrum of drug-loaded PLC microspheres 
(Figure 4) showing the presence of both the drug and the polymer 
were observed. Bands at 1743(-C=O ketone), 1450 (-CH3 aliphatic 
alkane), 1183 (-C-O ester) refer to the polymer. Bands at 2922 and 
2858 cm-1 also corresponds to the stretching vibration of aliphatic ă
C-H of the polymer. As for the drug, it is characterized by the band 
at 1690 (C=C alkene), the broad band at 3300-3400 cm-1 of the ă
OH (alcohol) and ăNH2 (amine) groups. 
The stability of microspheres was studied by examining the 
changes in their morphology over a storage period of 3 months. 
The microphotographs taken within this period revealed a spherical 
profile, which confirmed the resistance of microspheres to 
degradation (Figure 5). After that period, the degradation started to 
occur showing a non-spherical shape. 
The in vitro release profile was found to be strongly dependent on 
the %DL of different AmB formulations (Figure 6).  
The fastest release time was observed for F3 and F4 with the 
highest %DL. A burst release took place for these formulations 
after 2 to 3 days only. The complete release then needed 
approximately one week. As for the other formulations, a controlled 
extended release was observed during the first week, which was 
later followed by a less significant burst effect. The complete drug 
release required 12 to 13 days. 
AmB release from PLC microspheres took place by a diffusion 
mechanism through the polymeric matrix, as droplets form the 
aqueous release medium (PBS) were percolating inside the 
microspheres [24, 25]. This drug has a poor water-solubility, thus a 
low affinity to the aqueous buffer medium. This low affinity could 
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explain the slow diffusion through the porous matrix system. This 
has led in turn to the slow drug release, which required a period of 
1 to 2 weeks for most of the formulations. 
Conclusion 
The efficiency of the solvent evaporation technique in the 
formulation of a new DDS has been shown by the significant 
encapsulation percentages of drug within microspheres in this 
study. The AmB-loaded PLC microspheres exhibited a spherical  
 
profile, with a porous surface, as well as homogenous particle 
sizes and stability against degradation after three months of 
storage. The in vitro release of AmB from the PLC microspheres  
required several days due to the hydrophobic character of the drug. 
The copolymers of PLA and PCL have been found as promising 
materials in the formulation of microspheres for the sustained 
release of AmB. 
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